LIT-927

orally active CXCL12 neutraligand

Also Known As:

2(1H)-Pyrimidinone, 4-(4-chlorophenyl)-6-(4-hydroxy-3-methoxyphenyl)-; 4-(4-Chlorophenyl)-6-(4-hydroxy-3-methoxyphenyl)-2(1H)-pyrimidinone; 4-(4-Chlorophenyl)-6-(4-hydroxy-3-methoxyphenyl)pyrimidin-2(1H)-one

Networked: 1 relevant articles (0 outcomes, 0 trials/studies)

Bio-Agent Context: Research Results

Heterocyclic Compounds: 198
- 1-Ring Heterocyclic Compounds
  - Pyrimidines: 510
    - Pyrimidinones: 71
      - LIT-927: 1

Experts

1.	Bonnet, Dominique: 1 article (01/2020)
2.	Bordenave, Jennifer: 1 article (01/2020)
3.	Cumont, Amélie: 1 article (01/2020)
4.	Frossard, Nelly: 1 article (01/2020)
5.	Galzi, Jean-Luc: 1 article (01/2020)
6.	Guignabert, Christophe: 1 article (01/2020)
7.	Hibert, Marcel: 1 article (01/2020)
8.	Huertas, Alice: 1 article (01/2020)
9.	Humbert, Marc: 1 article (01/2020)
10.	Marsol, Claire: 1 article (01/2020)

Related Diseases

Hypoxia (Hypoxemia)

01/01/2020 - "Male Wistar rats were injected with monocrotaline (MCT) or were subjected to SU5416 followed by 3-week hypoxia to induce severe PH. After PH establishment, assessed by pulsed-wave Doppler echocardiography, MCT-injected or SU5416 plus chronic hypoxia (SuHx) rats were randomized to receive CXCL12 neutraligands chalcone 4 or LIT-927 (100 mg/kg/day), the C-X-C motif chemokine receptor 4 (CXCR4) antagonist AMD3100 (5 mg/kg/day), or vehicle, for 2 or 3 weeks, respectively. "

Related Drugs and Biologics

1.	Chemokine Receptors
2.	Monocrotaline
3.	Chalcone (Benzalacetophenone)
4.	Semaxinib (SU5416)
5.	plerixafor